Monday, June 24, 2019
Matteo Costacurta, MD
Peter MacCallum Cancer Centre
University of Melbourne
“A genome-wide CRISPR screen identifies TOP2B as an acquired druggable vulnerability in the context of IMiD resistance” (Potential implications in multiple myeloma and lymphoma therapy)
No Comments to "Matteo Costacurta, MD-VIMM Seminar"